{"id":"W2058887247","doi":"10.1016/j.jhep.2012.06.014","title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial","year":2012,"lang":"en","type":"article","venue":"Journal of Hepatology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":821,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto General Hospital","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Instituto de Salud Carlos III; Bayer HealthCare; Onyx Pharmaceuticals; National Institutes of Health; Ministerio de Ciencia e Innovación; European Commission","keywords":"Sorafenib; Medicine; Internal medicine; Hepatocellular carcinoma; Placebo; Hazard ratio; Adverse effect; Subgroup analysis; Oncology; Randomized controlled trial; Gastroenterology; Surgery; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004369233,0.0001965236,0.001257028,0.0004195239,0.00002452094,0.000002372353,0.0000809565,0.0001349666,0.00005265925],"category_scores_gemma":[0.0001187833,0.0001375958,0.000177974,0.0002800148,0.0001564024,0.0001588644,0.00002830942,0.000213023,6.969676e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006211932,"about_ca_system_score_gemma":0.0001790983,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004903078,"about_ca_topic_score_gemma":0.000006259637,"domain_scores_codex":[0.9979971,0.0001769433,0.001071274,0.0001393561,0.0003147294,0.0003005977],"domain_scores_gemma":[0.9982831,0.0001864674,0.0008472735,0.0001962184,0.0002811926,0.0002057267],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1498627,0.003012417,0.8428681,0.00008193484,0.0002792419,0.00009468601,0.0003920785,4.192117e-7,0.0009060024,0.00002152403,0.00001201771,0.002468923],"study_design_scores_gemma":[0.4892155,0.01503225,0.4733277,0.0001872121,0.001539202,0.0001927388,0.0001124539,0.0002320679,0.01971402,0.0000141992,0.0002302066,0.0002024106],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959813,0.002970531,0.00004887709,0.00009085792,0.0001219352,0.0007098538,0.000007905443,0.00000360109,0.00006514734],"genre_scores_gemma":[0.998957,0.00009657603,0.0008130567,0.00002052378,0.00006361047,0.000006114768,0.00001683107,0.00001896368,0.00000734235],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3695403,"threshold_uncertainty_score":0.5610992,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03640248984324077,"score_gpt":0.2820490078989289,"score_spread":0.2456465180556881,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}